Beyond Air® Approved to Initiate Clinical Study at 150 ppm Nitric Oxide with LungFit™ for the Treatment of Acute Viral Pneumonia Including COVID-19

Ads

You May Also Like

Shire plc : Director Declaration

Director Declaration July 25, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") ...

Dr. Yaron Pereg Appointed as New Chief Development Officer

TEL AVIV, Israel, Jan. 30, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), ...

Aptevo Therapeutics Extends Cash Runway $20 Million; Retains Term Loan Agreement With MidCap Financial

SEATTLE, Sept. 28, 2017 (GLOBE NEWSWIRE) -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company ...